(Total Views: 486)
Posted On: 05/28/2022 2:26:08 PM
Post# of 155814
and to add to this,
I feel Kelly was that vague because he is under a NDA. I feel CytoDyn has the data but can not say. Not just CytoDyn.
When he discussed the compassionate use patients, he indicated they were sick and they do comprise a significant portion of the 3 trials packed into 1. The trial with carboplatin (10 patients), the basket trial (2 patients) and the compassionate use trial (16 patients).
To "progress this molecule much further", in addition to time, we also need money and therefore will be "looking for more development opportunities."
That's why I feel we are under NDA. They already know the data. They know our Overall Survivability and Progression Free Survival and so does the partner. I would think that Pestell knows as well... The money necessary to push mTNBC forward is pending.
I feel Kelly was that vague because he is under a NDA. I feel CytoDyn has the data but can not say. Not just CytoDyn.
When he discussed the compassionate use patients, he indicated they were sick and they do comprise a significant portion of the 3 trials packed into 1. The trial with carboplatin (10 patients), the basket trial (2 patients) and the compassionate use trial (16 patients).
To "progress this molecule much further", in addition to time, we also need money and therefore will be "looking for more development opportunities."
That's why I feel we are under NDA. They already know the data. They know our Overall Survivability and Progression Free Survival and so does the partner. I would think that Pestell knows as well... The money necessary to push mTNBC forward is pending.
(3)
(0)
